Clinical trials sponsored by drug manufacturers suggest that GLP-1 medications combined with diet and exercise can be ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an ...

A 2026 BMJ study found GLP-1 drugs like Ozempic carry a 37–68% higher alopecia risk vs. other diabetes medications. The post ...

If you are a Medicaid beneficiary who is prescribed a glugacon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes, ...

Demand for compounded GLP-1 drugs persists despite shortage resolutions ...

Despite the end of nationwide shortages of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the market for compounded GLP-1 RA alternatives remains strong, and some of these products are from ...

Combining GLP-1 agonists with progestins lowered endometrial cancer risk by 66% compared to progestins alone. The GLP-1 agonist/progestin combination outperformed metformin/progestins in reducing ...

Patients with obstructive sleep apnea prescribed GLP-1 receptor agonists showed reduced risk for cardiovascular events than ...

Starting Wednesday, the federal government is offering a selection of the brand name medications to certain Medicare and ...

Newer oral drugs related to semaglutide medications such as Ozempic reduced pleasure-driven eating in mice by quieting a deep ...

From mood boosts to unexplained fatigue, there are some side effects reported by GLP-1 users that you won’t find on the label ...

Objective To evaluate the association between use of newer glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide, ...